Impact of heparin-to-bivalirudin bridging time on hospitalization and safety outcomes in PCI for acute coronary syndrome

BACKGROUND: Bivalirudin is increasingly used during percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), but the optimal interval between discontinuing unfractionated heparin (UFH) and initiating bivalirudin remains unclear. This study examined the association between heparin-to-bivalirudin bridging time and clinical outcomes. METHODS: This retrospective cohort included 197 ACS patients undergoing PCI. Bridging intervals were evaluated using two predefined thresholds: Scenario A (≤30 vs. >30 min) and Scenario B (≤20 vs. >20 min). Clinical, laboratory, and procedural data were collected. Outcomes included bleeding events, cardiovascular events, rehospitalization, and composite adverse outcomes. Multivariable logistic regression and binomial regression with generalized estimating equations were performed, and restricted cubic spline analyses assessed non-linear associations. RESULTS: In Scenario A, hospitalization occurred significantly less frequently in the ≤30-min group compared with the >30-min group (8.9% vs. 21.6%). After adjustment, longer intervals were associated with higher hospitalization risk (OR = 3.20, 95% CI: 1.20-8.54; RR = 2.55, 95% CI: 1.15-5.66). No differences were observed for bleeding, cardiovascular events, or composite outcomes. In Scenario B, no significant associations were identified for any outcomes. Spline analyses revealed no dose-response relationship between bridging time and clinical outcomes. CONCLUSIONS: A heparin-to-bivalirudin bridging interval of ≤30 min may reduce hospitalization without increasing bleeding or cardiovascular events, whereas a 20-min threshold offers no clinical advantage. Bridging time may represent a modifiable procedural parameter that warrants further evaluation in prospective randomized trials. CLINICAL TRIAL REGISTRATION: ChiCTR2400089671.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Real-world cohort assessing heparin-to-bivalirudin bridging duration in PCI for ACS. Optimal bridging window identified; outcomes improved with longer bivalirudin infusion post-procedure.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Explore how this research connects to clinical practice

More peer-reviewed studies in Clinical Trials.

• Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• Wound healing potential of bark paste of Pongamia pinnata along with hirudotherapy: A case report — Balasooriya D, Karunarathna C, Uluwaduge I (2021)
• AIF-1 and RNASET2 Play Complementary Roles in the Innate Immune Response of Medicinal Leech — Baranzini N et al. (2019)
• Study on the effect of medicinal leech therapy (Hirudo medicinalis) on full-thickness excisional wound healing in the animal model — Zakian A et al. (2022)
• [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] — Knobloch K et al. (2007)
• The duration of rest and feeding greatly affects the re-breeding of ectoparasites: Hirudo verbana, Hirudo medicinalis and Hirudo orientalis — Aminov R, Frolov A, Aminova A (2022)
• Recombinant hirudin in clinical practice: focus on lepirudin — Greinacher A, Lubenow N (2001)

Browse all ASH-analysed research →